NGM Open Innovation is focused on inflammation as part of a pathway-focused approach to treating neurological diseases. We are particularly interested in how perturbed neuroinflammatory and immunoregulatory processes contribute to a number of CNS diseases including Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia.
Microglial cells, acting as the innate immune cells of the CNS, are central mediators of these processes and regulate production of inflammatory cytokines, neuronal repair, and clearance of pathogenic protein and cell debris. Understanding how disruption of these cellular processes might underpin disease pathology and has therefore become a focus of intensive research. Furthermore, this research has been accompanied by the identification of neurodegenerative disease susceptibility genes linked to immunoinflammation pathways. These genetic variants not only provide a basis to identify novel pathways for targeted intervention, but also to enable the identification of specific patient populations that are most likely to benefit from such approaches.
If you would like to discuss opportunities to work with NGM Open Innovation in this area please contact us at email@example.com